Vacuum curettage was performed on 348 women who had received various regimens of oestrogen treatment for an average of 9 7 months for climacteric symptoms. In 62 cases (18%) the specimens were unsatisfactory for histological assessment; among the remainder, however, they showed a normal endometrium in 257 cases (90%), cystic hyperplasia in 21 (7%), adenomatous hyperplasia in 7 (2%), and endometrial adenocarcinoma in one.
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British Mcdical_Journal, 1978 , 1, 1575 -1577 Summary and conclusions Vacuum curettage was performed on 348 women who had received various regimens of oestrogen treatment for an average of 9 7 months for climacteric symptoms. In 62 cases (18%) the specimens were unsatisfactory for histological assessment; among the remainder, however, they showed a normal endometrium in 257 cases (90%), cystic hyperplasia in 21 (7%), adenomatous hyperplasia in 7 (2%), and endometrial adenocarcinoma in one.
Cyclical unopposed oral oestrogen treatment (98 cases) was associated with a 12% incidence of endometrial hyperplasia, but among those given an additional fiveday course of progestogen in each cycle (37 cases) the incidence was only 8%. No case of hyperplasia occurred among 102 women taking regimens including 10 or 13 days of progestogen. Among women treated with subcutaneous oestradiol implants and monthly five-day courses of oral progestogen (50 cases) there was a 28% incidence of hyperplasia including the one case of carcinoma, though some of those with hyperplasia may not have taken the full course of progestogen. Regular withdrawal bleeding during treatment was associated with a lower incidence of endometrial hyperplasia (6%) than unscheduled breakthrough bleeding (28%), but the one patient with carcinoma had experienced regular bleeding only.
Introduction
The part played by oestrogen treatment in the development of endometrial adenocarcinoma remains uncertain despite several retrospective studies'-3 and close scrutiny of the findings by later workers.4-6 This is of great importance for the many menopausal women being given oestrogens, but final clarification may not be possible until larger, better controlled, and possibly prospective studies are completed; these will necessarily be of long duration.
We therefore report, as part of a continuing prospective study, our observations on the effect of various regimens of hormone treatment on the endometrium of menopausal women and the incidence of abnormal endometrial histology, with particular reference to differences in their bleeding patterns.
Patients and methods
The 348 women studied had been receiving oestrogen treatment for 4-42 months (mean 9 All the histology was reported on by a single observer (TW-E). For ease of presentation the histological findings are classified as (a) normal-that is, indistinguishable from normal proliferative or secretory endometrium, menstrual or atrophic; (b) abnormal-namely, cystic hyperplasia, adenomatous or atypical hyperplasia of whatever grade, or frank adenocarcinoma; or (c) unsatisfactory-that is, insufficient material for examination.
Particular note was made of any bleeding during treatment. Withdrawal bleeding starting either during a tablet-free week or after the completion of a course of progestogen was classed as "scheduled" bleeding, whereas bleeding that started at any other time was classed as "unscheduled" bleeding. Table IV gives the relation between the bleeding pattern and histological findings. Only 13 of the 33 women in the no-bleeding group produced satisfactory specimens, but all of these were normal. The proportion with abnormal histology was highest (28 %) among the women with unscheduled bleeding, though among those with scheduled bleeding the proportion was still 6 /, which included the one case of carcinoma. 
Results

Discussion
The part played by oestrogens is the question of greatest practical importance among the many remaining unanswered about the aetiology of endometrial adenocarcinoma. That such hormones cause cystic hyperplasia is incontrovertible, so that the simple hyperplasias can virtually be defined as the endometrial states resulting from prolonged oestrogenic stimulation, but the relation between cystic hyperplasia and adenocarcinoma is not understood.
Although steady oestrogenic stimulation plays a part in the genesis of some of the other endometrial lesions classified as hyperplasia, their investigation is hampered by a lack of agreed definition for the histological terms used and the subjective nature of their diagnosis. Without doubt some carcinomas develop from endometria in which glandular growth exceeds stromal-that is, from adenomatous hyperplasias-particularly when there is epithelial "atypia," in the severe or atypical forms, but what proportion do so remains unknown. Furthermore, it is difficult to find objective criteria for deciding when a complex hyperplasia has passed the point at which it will regress when any known cause is removed or when it can be modified by other stimuli such as progestogens.
Cyclical unopposed oral oestrogen, usually with a tablet-free week, is the most widely prescribed treatment of climacteric symptoms. It has been assumed to be safe because it allows the stimulated tissue either to regress or to break down and be shed, so avoiding a cumulative effect of oestrogen. These assumptions, however, were not supported in an earlier report of ours" and are strongly contradicted by our present results.
For the pattern of cystic hyperplasia to develop, oestrogen stimulation must be continued for many weeks or some months, and we find that 1l01, of women given cyclical oral oestrogen have this pattern after a few months, though higher incidences have been reported with longer durations of treatment. 9 Although the relation between cystic hyperplasia and carcinoma is uncertain, at least the former lesion indicates prolonged oestrogenic activity, and it seems wise, while doubt remains about the longterm importance of such stimulation, not to use regimens that lead to its occurrence.
In contrast, when oral progestogen had been added to oral oestrogen only one out of 138 women had this pattern, and four patients who had cystic or mild adenomatous hyperplasia of the endometrium during unopposed oestrogen treatment were found to have normal endometrial patterns after two months of Menophase treatment.
An even higher incidence of cystic hyperplasia was found in patients with implants than among those given unopposed oral oestrogen, even though they had been prescribed additional oral progestogen. This, however, suggests that a five-day course of norethisterone 5 mg is insufficient to modify the endometrium after stimulation by sustained circulating oestrogen concentrations produced by implanted oestradiol."' Adding a course of progestogen to oestrogen treatment has been advocated for many years 6 1-13 but at present it is incorporated in about only 6",, of prescriptions for menopausal oestrogen treatment in the United Kingdom." Our findings show the value of additional progestogen and that it is probably the duration rather than the total dosage of progestogen that is important in producing a protective effect on the endometrium."' 16 Those women who received a total of 25 mg norethisterone over five days in addition to either oral or implanted oestrogen were not so well protected from hyperplasia as the women given a total of 15 mg norethisterone over 13 days from Menophase treatment.
For most menopausal women receiving hormone treatment vacuum curettage is not readily available, so it would be reassuring to be able to exclude endometrial abnormalities by clinical findings alone. While the proportion of patients with abnormal histological findings was, as expected, greatest among those with unscheduled or breakthrough bleeding (2800 of all those from whom adequate specimens were obtained), 600 of specimens from those with scheduled bleeding were also abnormal. Only a few of those with such a bleeding pattern who were having combined oral progestogen and oestrogen had lesions (1.50l)), but the proportion rose to 12`" 0 among those having unopposed cyclical oestrogen, and to 180o among those with implants. Clearly the pattern of bleeding does not exclude abnormality, and the one case of carcinoma was associated with regular scheduled bleeding.
We believe that already the results of this study have important implications for the routine management of women with climacteric symptoms and that the potential risk of endometrial carcinoma from oestrogen treatment may be reduced by wider adoption of the following measures: (1) avoiding the use of unopposed oestrogen treatment; (2) adding more than five days and probably at least 10-13 days of a progestogen; (3) regular endometrial curettage of patients who are not receiving adequate additional progestogen; and (4) recognising that a regular bleeding response to oestrogen treatment provides no guarantee of a healthy endometrium.
